temozolomide has been researched along with pha 848125 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G | 1 |
| Albanese, C; Alzani, R; Amboldi, N; Brasca, M; Ciomei, M; Degrassi, A; Festuccia, C; Fiorentini, F; Galvani, A; Gravina, G; Mercurio, C; Pastori, W; Pesenti, E | 1 |
2 other study(ies) available for temozolomide and pha 848125
| Article | Year |
|---|---|
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Genes, p53; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Pyrazoles; Quinazolines; Temozolomide; Tetrazolium Salts; Thiazoles | 2010 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Synergism; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2013 |